Clinical and genetic studies further support the role of HVEM as an immune checkpoint, with altered HVEM and BTLA expression profiles identified in patients with IBD and other gastrointestinal disorders (36, 54). This evidence concerns the gene TNFRSF14 and inflammatory bowel disease.